Quincy Bioscience: Receives investment capital from DaneVest

Madison, Wis — (August 25, 2010) Quincy Bioscience, a research-based biotechnology company, announced it has recently received a capital infusion from DaneVest Tech Fund I, a Madison-based investment group which specializes in privately held technology companies. The additional funding will be used thelp support national sales of the company’s growing brand, Prevagen® – Brain Cell Protection.

“We are pleased to announce the partnership of DaneVest Tech Fund,” said Michael J. Beaman, CEO at Quincy Bioscience. “2010 has been a banner year for Quincy Bioscience in terms of intellectual property development, research results on Prevagen’s active ingredient apoaequorin, and Prevagen sales growth. This investment will accelerate our goal to make Prevagen a national brand.”

Terrence R. Wall, Manager and Principal of DaneVest Tech Fund said, “We are excited to be partnering up with this fast growing local company, their strong management team and their exciting product offerings.”

Prevagen is an over-the-counter brain health product launched in 2007 that has proven to improve cognitive performance in those with memory concerns in sixty days compared to placebo. Prevagen contains the active ingredient apoaequorin, a calcium-binding protein which helps to buffer excess calcium from damaging neurons in aging.

About Quincy Bioscience

Quincy Bioscience is a biotechnology company based in Madison, Wisconsin. Quincy Bioscience is focused on the discovery, development and commercialization of novel compounds to fight the aging process. The company’s products focus on restoring calcium balance related to neurodegenerative disorders and other destructive age-related mechanisms.

About DaneVest Tech Fund I

DaneVest Tech Fund invests in privately held, early stage growth businesses with special technology and other advantages in the information technology, life science and consumer goods/service industries. Special consideration is given to companies with revenues and available Act 255 Wisconsin tax credits. The Fund’s portfolio companies are primarily located in Wisconsin.